The efficacy of cancer immunotherapy depends highly on the potency and duration of the induced immune response. To date, cancer vaccinations have utilized intact tumor cells, naive proteins, CTL-defined peptides, nucleic acids, cell membranes and recombinant viruses as well as genetically modified tumors. Although some approaches have been to increase the antigen presenting capacity of tumor cells, in most cases, the dominant role of host antigen-presenting cells (APCs) has been demonstrated. Among various APCs, dendritic cells (DCs) seem to have the essential properties required for eliciting T-cell responses: migration and homing, antigen processing and presentation and co-stimulation. Recently, DCs have been used to present tumor antigens. This is generally achieved by pulsing DCs with peptides, tumor lysates or RNA derived from neoplastic cells. It has also been demonstrated that immunization with DC-tumor fused chimeric cells results in the regression of established metastases. Fused cells should have the ability to elicit both MHC class I and II-restricted responses by processing and presenting known and undefined tumor antigens. In most reported cases, however, fusion has been accomplished with the use of PEG, resulting in low efficiency and high toxicity. With this approach, it may be the technical rather than conceptual aspects that limit its application. The applicant has recently demonstrated that fusion of DCs and tumor cells by applying electric field pulses is at least 10-fold more efficient than that by PEG. Interestingly, electrofusion of immature DCs with tumor cells resulted in hybrid cells having characteristics of mature DCs with high expression of MHC class II, B7.1 and B7.2 molecules. To analyze biological and immunological functions of these artificially generated chimeric cells, the current application will utilize the well-characterized model tumor-associated antigen, B-galactosidase, to address fundamental issues. Subsequent experiments will use several weakly and poorly immunogenic tumors. The goal of the current application is to develop in murine models, the principles and methodologies for utilizing DCs fused with entire tumor cells for active and adoptive immunotherapy of cancer.
The specific aims are: 1) To optimize electrofusion techniques; 2) To characterize antigen processing and presentation, MHC restriction and trafficking patterns of fused cells; 3) To analyze characteristics of immune responses elicited by DC-tumor fused cells; 4) To explore the therapeutic potential of the chimeric cells; and 5) To develop methods for primary in vitro immunization for generating tumor-specific T cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA084110-02
Application #
6377653
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Muszynski, Karen
Project Start
2000-07-01
Project End
2005-06-30
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
2
Fiscal Year
2001
Total Cost
$333,000
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Type
DUNS #
017730458
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Kjaergaard, Jorgen; Wang, Li-Xin; Kuriyama, Hideyuki et al. (2005) Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 103:156-64
Kuriyama, H; Shimizu, K; Lee, W et al. (2004) Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. Dev Biol (Basel) 116:169-78; discussion 179-86
Shimizu, Keiji; Kuriyama, Hideyuki; Kjaergaard, Jorgen et al. (2004) Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J Immunother 27:265-72
Kjaergaard, Jorgen; Shimizu, Keiji; Shu, Suyu (2003) Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 225:65-74
Kjaergaard, Jorgen; Peng, Liaomin; Cohen, Peter A et al. (2003) Therapeutic efficacy of adoptive immunotherapy is predicated on in vivo antigen-specific proliferation of donor T cells. Clin Immunol 108:8-20
Tanaka, Hiroshi; Shimizu, Keiji; Hayashi, Takashi et al. (2002) Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 220:1-12
Hayashi, Takashi; Tanaka, Hiroshi; Tanaka, Junta et al. (2002) Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin Immunol 104:14-20